Eileen Parkes
MB BCh, Ba(O) (Hons), MRCP (Onc), PhD
ASSOCIATE PROFESSOR, INNATE TUMOUR IMMUNOLOGY, Group leader
- Consultant Medical Oncologist, Early Phase Trials
RESEARCH SUMMARY
- Understand resistance mechanisms to immune-targeting treatments in cancer;
- Characterise the role of the interaction of chromosomal instability and DNA repair deficiency with immune activation in tumour initiation, progression and response.
- Study tumour microenvironment, fibroblasts and extracellular matrix in chromosomally unstable cancers.
In the Parkes Lab we study intrinsic inflammatory pathways in cancer. These are important immune pathways, present in all cells, that act as emergency response pathways to viral infection. However, in cancer, these pathways can be rewired and hijacked by the tumour to promote growth, invasion and metastasis.
Recent publications
-
Targeting mitotic regulators in cancer as a strategy to enhance immune recognition.
Journal article
Gregorczyk M. and Parkes EE., (2023), DNA repair, 132
-
Non-cell-autonomous cancer progression from chromosomal instability.
Journal article
Li J. et al, (2023), Nature, 620, 1080 - 1088
-
Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1.
Journal article
Sugiyarto G. et al, (2023), Journal for immunotherapy of cancer, 11
-
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Journal article
Pencik J. et al, (2023), Molecular cancer, 22
-
cGAS-STING signalling in cancer: striking a balance with chromosomal instability.
Journal article
Beernaert B. and Parkes EE., (2023), Biochemical Society transactions, 51, 539 - 555